COLOMBO NICOLETTA
Pubblicazioni
Lorusso, D., Oaknin, A., Borges, G., Damian, F., Ottevanger, N., Van Gorp, T., et al. (2025). Cemiplimab plus peltopepimut-S vaccine in recurrent cervical cancer: A phase 2 clinical trial. GYNECOLOGIC ONCOLOGY, 196(May 2025), 28-35 [10.1016/j.ygyno.2025.03.019]. Dettaglio
De Vitis, L., Schivardi, G., Gaeta, A., Caruso, G., Rosanu, M., Ribero, L., et al. (2025). External validation of the Annual Recurrence Risk Model (ARRM) for tailored surveillance strategy in patients with cervical cancer. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 35(6 (June 2025)) [10.1016/j.ijgc.2025.101756]. Dettaglio
Lorusso, D., Colombo, N., Dubot, C., Cáceres, M., Hasegawa, K., Shapira-Frommer, R., et al. (2025). Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study. ANNALS OF ONCOLOGY, 36(1), 65-75 [10.1016/j.annonc.2024.10.002]. Dettaglio
Quesada, S., Penault-Llorca, F., Matias-Guiu, X., Banerjee, S., Barberis, M., Coleman, R., et al. (2025). Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics. EUROPEAN JOURNAL OF CANCER, 215(17 January 2025) [10.1016/j.ejca.2024.115169]. Dettaglio
Bogani, G., Moore, K., Ray-Coquard, I., Lorusso, D., Matulonis, U., Ledermann, J., et al. (2025). Incorporating immune checkpoint inhibitors in epithelial ovarian cancer. GYNECOLOGIC ONCOLOGY, 193(February 2025), 30-40 [10.1016/j.ygyno.2024.12.011]. Dettaglio